THE use of "resin microspheres" for the treatment of advanced Hepatocellular Carcinoma (HCC) or primary liver cancer, the sixth most common cancer worldwide, has proven to be superior to current standard of care therapy, namely twice-daily oral doses of sorafenib (Bayer's Nexavar), according to new research data released this week.
The Asia-Pacific Study presented at the 2017 American Society of Clinical Oncology Meeting revealed that one-time administration of microspheres showed a significantly better tumour response rate of 16.5% than sorafenib with its 1.7% tumour response rate, and reportedly less adverse events.
Dubbed SIR-Spheres Y-90 Resin Microspheres, the product provided "a significant increase in the overall Progression-Free Survival rate of 6.3 months".
Visit sirtex.com for the data.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jun 17